Malnupiravir: The first oral drug for covid-19

Malnupiravi is the first oral drug to treat covid in the world.

The BBC has learned that Beximco Pharmaceuticals launched the drug on Tuesday under the name “Amorivir 200”. Referring to SKF Pharmaceuticals, the Department of Pharmaceutical Administration says their malt will hit the market by Wednesday. And Square Pharmaceuticals told the BBC they would be able to bring the medicine to market in two or three days. Ahmed Kamrul Alam, Marketing Director at Square Pharmaceuticals, told the BBC they planned to keep the price of each pill between 50 and 60 rupees.

The Finnish Medicines Agency has already granted permission to all three companies to manufacture and market Malnupiravia. Major General Mahbubur Rahman, director-general of the department, said at a news conference on Tuesday that he had approved the emergency use and manufacture of the drug. “The oral drug Malnupiravir has been approved as an antiviral drug for emergency use in the treatment of Kovid,” he said.

A total of 10 companies applied for the manufacture and marketing of the drug. Beximco, Square, and SKF have been approved, while the other seven are awaiting approval, the drug agency said at a news conference. Malnupiravir has previously been approved for use in patients in the United Kingdom and the United States.

What is Malnupiravi?

Malnupiravi tablet or pill. Coronavirus therapy This medicine is given twice a day to high-risk patients. Initially, this drug was made to treat the flu. Clinical studies have shown that this drug halves the risk of hospitalization and death in patients. Coronavirus therapy is the first drug to be taken orally, not intravenously.

It is the first oral drug to treat coronavirus, developed by the US pharmaceutical company Mark, Sharp & Dome (MSD) and Rizbak Biotherapeutics. The UK has already agreed to buy 460,000 courses of medication. The first shipment is expected to arrive in November.

According to a national study in the United Kingdom, the medicine is initially given to both vaccinated and non-vaccinated patients. The next decision about this medicine will only be made after analyzing the information provided to them.

The best results are obtained if the patient is given within five days of the onset of covid symptoms. How does Malnupiravir work? This new treatment works by targeting a specific viral enzyme. By using this enzyme, the virus produces more and more viruses like itself. This medicine causes a defect in the genetic code of the virus that prevents the virus from dividing. As a result, the amount of virus in the body is reduced and, as a result, the severity of the disease is reduced.

Mark says the treatment should be just as effective in newer variants of the virus. According to the MHRA, the UK’s medical and health regulator, the tablet is approved for use in patients with mild to moderate symptoms and at least one health risk such as obesity, aging, diabetes, or heart disease.

“This drug has been added as a new tool in the fight against Covid-19,” said June Raine, the company’s CEO. “It’s the world’s first approved antiviral drug for a disease that can be taken orally without intravenous administration,” he said. “This is important because it means that Kovid-19 can be treated outside the hospital before it reaches a critical stage.”

How effective?

According to the director-general of the Department of Medicine, Malnupiravi can reduce the hospitalization and mortality of patients by treating Kovid.

The BBC reports that a clinical study of Malnupiravir has recently been performed in 75 patients with covid. The findings are:

• 7.3% of those treated were hospitalized
• which is half of the normal pill given to 14.1% of patients.
• None of those given Malnupiravi died. However, eight other drug patients in the study died in Kovid.

The results of the clinical trial were published in a press release and have not yet been evaluated.

However, it is known from the data that Malnupiravi should be taken immediately after the onset of symptoms in order for the medicine to be effective. The study in previously hospitalized patients was postponed due to a lack of results. In the approval document, the MHRA recommends starting the drug as soon as possible after a positive covid test. It is recommended to start using within five days of the onset of symptoms.

Penny Ward, a professor at King’s College London who was not involved in the study, said: “If these results work in the same way for the UK population, the number of patients in need of hospitalization can be halved and the number of deaths reduced. Significantly reduced.”

“It looks like it’s likely to be restricted to people at high risk of complications from the disease – for example, the elderly who suffer from heart disease.

Best GFX tools for Pugb lite